CN112755108A - 一种中药组合物在制备呼吸系统炎症防治药物中的用途 - Google Patents
一种中药组合物在制备呼吸系统炎症防治药物中的用途 Download PDFInfo
- Publication number
- CN112755108A CN112755108A CN201911058534.9A CN201911058534A CN112755108A CN 112755108 A CN112755108 A CN 112755108A CN 201911058534 A CN201911058534 A CN 201911058534A CN 112755108 A CN112755108 A CN 112755108A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- group
- effect
- pneumonia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 72
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 14
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 14
- 210000002345 respiratory system Anatomy 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title abstract description 16
- 210000004072 lung Anatomy 0.000 claims abstract description 31
- 206010035664 Pneumonia Diseases 0.000 claims abstract description 23
- 244000052616 bacterial pathogen Species 0.000 claims abstract description 9
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 7
- 230000000241 respiratory effect Effects 0.000 claims abstract description 6
- 241000193998 Streptococcus pneumoniae Species 0.000 claims abstract description 5
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims abstract description 5
- 241000700159 Rattus Species 0.000 claims description 26
- 210000000440 neutrophil Anatomy 0.000 claims description 15
- 206010006451 bronchitis Diseases 0.000 claims description 14
- 108090001005 Interleukin-6 Proteins 0.000 claims description 13
- 102000003777 Interleukin-1 beta Human genes 0.000 claims description 12
- 108090000193 Interleukin-1 beta Proteins 0.000 claims description 12
- 241001116389 Aloe Species 0.000 claims description 9
- 235000011399 aloe vera Nutrition 0.000 claims description 9
- 210000000265 leukocyte Anatomy 0.000 claims description 9
- 206010011224 Cough Diseases 0.000 claims description 8
- 241000208340 Araliaceae Species 0.000 claims description 7
- 244000183685 Citrus aurantium Species 0.000 claims description 7
- 235000007716 Citrus aurantium Nutrition 0.000 claims description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 7
- 235000008434 ginseng Nutrition 0.000 claims description 7
- 241001289529 Fallopia multiflora Species 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 4
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 4
- 235000017784 Mespilus germanica Nutrition 0.000 claims description 3
- 244000182216 Mimusops elengi Species 0.000 claims description 3
- 235000000560 Mimusops elengi Nutrition 0.000 claims description 3
- 235000007837 Vangueria infausta Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 claims description 2
- 108010052008 colla corii asini Proteins 0.000 claims description 2
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 2
- 241000092665 Atractylodes macrocephala Species 0.000 claims 1
- 241000588748 Klebsiella Species 0.000 claims 1
- 101100381517 Mus musculus Bcl2 gene Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 23
- 208000037883 airway inflammation Diseases 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 7
- 241000588747 Klebsiella pneumoniae Species 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 229940088597 hormone Drugs 0.000 abstract description 2
- 239000005556 hormone Substances 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 25
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 20
- 229960003957 dexamethasone Drugs 0.000 description 20
- 239000002689 soil Substances 0.000 description 20
- 101150064015 FAS gene Proteins 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 14
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 13
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 12
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 7
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 210000000621 bronchi Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 5
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 5
- 230000003385 bacteriostatic effect Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000003437 trachea Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 241000132012 Atractylodes Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000287420 Pyrus x nivalis Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 241001547127 Fritillaria cirrhosa Species 0.000 description 2
- 244000241872 Lycium chinense Species 0.000 description 2
- 235000015468 Lycium chinense Nutrition 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 238000010161 Student-Newman-Keuls test Methods 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940012022 pentobarbital sodium 50 mg Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000008203 tachypnea Diseases 0.000 description 1
- 206010043089 tachypnoea Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于医药领域,具体涉及一种中药组合物在制备呼吸系统炎症防治药物中的用途。本发明提供的中药组合物在对呼吸系统炎症进行治疗时,各组分具有显著的协同增效作用,疗效显著、作用全面,对肺炎克莱伯杆菌、金黄色葡萄球菌及肺炎链球菌等常见的肺炎致病菌均具有显著的抑制作用。在有效消除气道炎症的同时还能快速恢复肺部组织正常生理结构,并且其效果显著好于现有中成药、相当于现有激素类药物对炎症的治疗作用,在对呼吸系统炎症的治疗方面具有很好的应用前景。
Description
技术领域
本发明属于医药领域,涉及一种中药组合物在制备呼吸系统炎症防治药物中的用途。
背景技术
机体在进行新陈代谢过程中,经呼吸系统不断地从外界吸入氧,由循环系统将氧运送至全身的组织和细胞,同时将细胞和组织所产生的二氧化碳再通过循环系统运送到呼吸系统排出体外。因此,呼吸系统由气体通行的呼吸道和气体交换的肺所组成。呼吸道由鼻、咽、喉、气管、支气管和肺内的各级支气管分支所组成。从鼻到喉这一段称上呼吸道;气管、支气管及肺内的各级支气管的分支这一段为下呼吸道。
呼吸系统炎症严重影响着人们的生活,季节更替时呼吸道疾病尤为多发,特别是以上呼吸道感染为代表的支气管炎和下呼吸道感染为代表的肺炎。而这两种炎症也是引起咳嗽、哮喘的主要发病机制之一。本发明提供了一种中药组合物的新用途,此组合物能对支气管炎、肺炎等气道炎症起到很好的治疗作用。
发明内容
本发明的主要目的为提供一种中药组合物在制备呼吸系统炎症防治药物中的用途。主要是针对已上市产品“首荟通便胶囊”开发的新适应症。首荟通便胶囊该产品的配方专利为CN100453105C,专利名称为一种具有通便排毒、减肥降脂功能的组合物及制备方法已经获得授权。
本发明的目的主要通过如下技术方案实现:
(1)体外抑菌试验结果表明:组合物组对三种肺炎致病菌均有显著的抑制作用,大部分单味中药对三种致病菌均耐药,只有枳实对金黄色葡萄球菌为中度敏感,上述结果表明:本发明提供的中药组合物对肺炎致病菌具有显著的抑制作用,并且组合物中各组分具有显著的协同增效作用。
(2)组合物对肺炎克莱伯杆菌致大鼠肺炎模型的治疗作用试验结果表明:地塞米松和组合物均能使肺炎模型大鼠的白细胞和中性粒细胞明显下降,差异有统计学意义(P<0.01),并且组合物组和地塞米松组相比无显著性差异,表明二者降低肺炎大鼠白细胞和中性粒细胞的功能相当。
地塞米松和组合物均能使大鼠肺组织的TNF-α,IL-1β,IL-6水平明显下降,差异均有统计学意义(P<0.01或P<0.05),并且组合物与地塞米松相比,二者对IL-1β,IL-6降低作用相当,无统计学差异,对TNF-α的降低作用有统计学差异(P<0.05),表明组合物对IL-1β,IL-6水平的降低作用和地塞米松相当,对TNF-α的降低作用稍弱于地塞米松。
此外,本发明提供的组合物可明显改善肺泡间质水肿和肺泡壁间质浸润的状态,使肺部组织恢复正常的生理状态。
(3)本发明提供组合物对支气管炎具有显著的治疗作用,可显著提高急性支气管炎小鼠Bcl-2蛋白表达,降低Fas蛋白表达,进而可使肺组织恢复正常的生理结构、减轻气道炎症的发生发展,并且效果显著好于川贝止咳糖浆的效果。
上述中药组合物由何首乌、芦荟、决明子、枸杞子、阿胶、人参、白术和枳实为原料药材制备而成。
其中各成分以重量份计为:何首乌60-150重量份 芦荟100-200重量份 决明子80-180重量份 枸杞子30-150重量份 阿胶30-150重量份 人参20-100重量份 白术20-100重量份 枳实50-200重量份,优选为:何首乌120重量份 芦荟160重量份 决明子140重量份 枸杞子75重量份 阿胶75重量份 人参50重量份 白术50重量份 枳实120重量份。
上述组合物中各成分按专利CN100453105C一种具有通便排毒、减肥降脂功能的组合物及制备方法得到。本发明提供的中药组合物还可以含有药学上可接受的辅料,所述的中药组合物制备成药物制剂,优选为为片剂,胶囊剂,颗粒剂。
其中,胶囊剂可按专利CN100453105C中提供的胶囊剂的制备工艺制备而成;片剂及颗粒剂可按常规的片剂、颗粒剂制备工艺制备。
将上述制剂应用于咳嗽的治疗时可取得与本发明提供的中药组合物同样的治疗效果。
上述中药组合物在用于咳嗽的治疗时的用药剂量为3mg/kg.d-300mg/kg.d,优选为30mg/kg.d。
本发明提供的组合物与现有药物相比,在对气道炎症进行治疗时具有如下优势:
1.协同增效,作用全面
本发明提供的组合物中各组分具有显著的协同增效作用,对肺炎克莱伯杆菌、金黄色葡萄球菌及肺炎链球菌等常见的肺炎致病菌均具有显著的抑制作用。
2.疗效显著
能显著降低肿瘤坏死因子(TNF)-α,IL-1β及IL-6等炎症因子的释放,降低炎症反应;可显著提高急性支气管炎小鼠Bcl-2,降低Fas,以减轻气道炎症的发生发展,从而治疗以气道炎症为主要发病机制的咳嗽、哮喘等症,并且效果显著好于现有中成药,相当于激素类治疗药物对炎性症状的治疗效果。
3.综合调理
本发明提供的组合物为中药成分,可调节脏腑、固本培源从整体上改变人体状态,增强免疫力,从而使气道的炎性状态得到改善。
具体实施例
为了使本领域技术人员充分了解本发明,以下通过具体的实施例进一步说明本发明,但本领域技术人员应该知晓,本发明实施例并不以任何方式限制本发明。
具体实施例1组合物体外抑菌试验
1材料
1.1菌种与培养基
肺炎克莱伯杆菌,金黄色葡萄球菌,肺炎链球菌均购自青岛绿谷商贸有限公司;胰蛋白胨大豆琼脂、胰蛋白胨大豆肉汤,购自北京陆桥技术有限公司。
1.2药品
本发明组合物及组合物中各单味中药有效成分均按专利CN100453105C中提供方法制备得到。
2方法
2.1菌液的制备
取保存的菌种接种于TSA培养基,置37℃培养24h使菌种活化,将活化的菌种取一环接种于1mLTSB液体培养基中,培养6h后,按照1:10000,稀释备用。
2.2中药提取物的配制
将中药提取物浓缩粉配制成液体制剂,组合物浓度为0.5g/mL,单味中药(何首乌、芦荟、决明子、枸杞子、阿胶、人参、白术及枳实)提取物浓度均为0.5g/mL,高压灭菌备用。
2.3抑菌试验
采用琼脂打孔法。用移液器分别吸取药液200μL注入用牛津杯打好的孔中,每种药做3个重复。将平板置37℃恒温箱中培养12-18h,用游标卡尺测量抑菌圈的直径,并取3个孔的平均值。
2.4判断标准
参考《中药药理学》中的标准:抑菌圈直径>15mm为高度敏感(++),≥10-≤15mm为中度敏感(+),<10mm为耐药(-)。
3结果与分析
组合物及各单药成分对三种菌株的抑菌检测结果。
表1各有效成分对三种菌株的抑菌检测结果
肺炎克莱伯杆菌 | 金黄色葡萄球菌 | 肺炎链球菌 | |
组合物组 | ++ | ++ | ++ |
何首乌组 | - | - | - |
芦荟组 | - | - | - |
决明子组 | - | - | - |
枸杞子组 | - | - | - |
阿胶组 | - | - | - |
人参组 | - | - | - |
白术组 | - | - | - |
枳实组 | - | + | - |
从表1中可以看出:组合物组对三种肺炎致病菌均有显著的抑制作用,大部分单味中药对三种致病菌均耐药,只有枳实对金黄色葡萄球菌为中度敏感,上述结果表明:本发明提供的中药组合物对肺炎致病菌具有显著的抑制作用,并且组合物中各组分具有显著的协同增效作用。
具体实施例2组合物对肺炎克莱伯杆菌致大鼠肺炎模型的治疗作用
1动物分组与模型制备
40只SD大鼠随机分成4组,每组10只,即:正常组、模型组、地塞米松组(1.04mg/kg)、组合物组(180mg/kg),所有大鼠经麻醉后,颈部消毒、备皮无菌操作,暴露大鼠上段气管,正常组大鼠采用1mL注射器经气管滴入生理盐水0.3mL,其余滴入菌液0.3mL,接种后立即竖立大鼠固定台,使大鼠保持直立位约20s,以保证接种菌液因重力作用而入肺。当大鼠出现反应迟钝、呆滞、呼吸急促,并伴有严重的低氧血症,SaO2<90%或动脉氧分压≤8kPa确诊为重症肺炎。对照组和模型组每天给予生理盐水20mL/kg灌胃1次,地塞米松组和组合物组按照20mL/kg体重灌胃1次,连续6d。
2指标观察
2.1苏木精-伊红(HE)染色观察肺组织病理学变化取大鼠左肺上叶,4℃生理盐水冲洗,滤纸拭干,10%中性甲醛溶液固定,石蜡包埋,常规切片,HE染色,光学显微镜下观察肝组织切片的病理变化。
2.2支气管肺泡灌洗液中白细胞及中性粒细胞检测
第6天给药24h后,戊巴比妥钠50mg/kg,ip麻醉。扎紧左主支气管,输液管套管插入主支气管3-4cm并固定,注入生理盐水10mL于肺腔,连续翻动右肺组织,抽回再灌注3次,抽出灌洗液。共灌洗3次,收集总灌洗液,计数白细胞和中性粒细胞。
2.3肺组织部分生化指标的测定
取左肺下叶200mg冰浴匀浆制成10%溶液,4℃、3 000r/min离心10min,取上清液。酶联免疫吸附法测定TNF-α,IL-1β,IL-6水平。
3统计学方法
采用SPSS 14.0统计软件分析数据。计量资料采用均数±标准差(x±s),多组间比较采用单因素方差分析,两两比较采用SNK-q法。计数资料采用百分率,统计学分析采用χ2检验,以P<0.05为差异有统计学意义。
4结果
4.1肺组织病理学变化
正常组大鼠肺组织无异常发生,结构清晰,无炎性反应和浸润的发生。模型组肺泡壁加厚,并伴有大量的中性粒细胞,肺泡间质出现水肿和肺泡壁间质浸润。地塞米松组和组合物组浸润明显减轻,部分出现少量的中性粒细胞、淋巴细胞以及脱落坏死的上皮细胞。4.2组合物对肺炎大鼠支气管肺泡灌洗液中白细胞和中性粒细胞的影响
与正常组比较,模型组大鼠支气管肺泡灌洗液中中性粒细胞、白细胞水平明显升高,差异有统计学意义(P<0.01),表明造模成功;与模型组比较,地塞米松组和组合物组的白细胞和中性粒细胞明显下降,差异有统计学意义(P<0.01),表明组合物与地塞米松均能降低肺炎大鼠白细胞和中性粒细胞水平,并且组合物组和地塞米松组相比无显著性差异,表明二者降低肺炎大鼠白细胞和中性粒细胞的功能相当。具体结果见表2。
表2组合物对肺炎大鼠白细胞和中性粒细胞的影响
组别 | 白细胞/ml | 中性粒细胞/ml |
正常组 | 308土10 | 541土23 |
模型组 | 1012土97<sup>##</sup> | 2012土147<sup>##</sup> |
地塞米松组 | 338土11<sup>﹩﹩</sup> | 643土109<sup>﹩﹩</sup> |
组合物组 | 402土85<sup>﹩﹩</sup> | 708土99<sup>﹩﹩</sup> |
与正常组相比,##p<0.01;
与模型组相比,﹩﹩p<0.01。
4.3组合物对肺炎大鼠TNF-α,IL-1β和IL-6的影响
与正常组比较,模型组大鼠中肺组织的TNF-α,IL-1β,IL-6水平明显增加,差异有统计学意义(P<0.01),表明造模成功。与模型组比较,地塞米松组和组合物组大鼠肺组织的TNF-α,IL-1β,IL-6水平明显下降,差异均有统计学意义(P<0.01或P<0.05),并且组合物组与地塞米松组相比,二者对IL-1β,IL-6相当,无统计学差异,对TNF-α的降低作用有统计学差异(P<0.05),表明组合物对IL-1β,IL-6水平的降低作用与地塞米松相当,对TNF-α水平的降低作用弱于地塞米松。具体结果见表3。
表3组合物物对肺炎大鼠肺组织TNF-α,IL-1β,IL-6的影响
组别 | TNF-α | IL-1β | IL-6 |
正常组 | 110.34土24.22 | 199.03土76.01 | 66.54土10.01 |
模型组 | 423.12土27.89<sup>##</sup> | 783.12土109.01<sup>##</sup> | 203.33土23.45<sup>##</sup> |
地塞米松组 | 143.26土34.09<sup>﹩﹩</sup> | 289.13土98.01<sup>﹩﹩</sup> | 101.34土17.56<sup>﹩﹩</sup> |
组合物组 | 289.23土29.00<sup>﹩&</sup> | 345.00土77.08<sup>﹩﹩</sup> | 135.78土21.23<sup>﹩﹩</sup> |
与正常组相比,##p<0.01;
与模型组相比,﹩p<0.05,﹩﹩p<0.01;
与地塞米松组相比,&p<0.05。
实施例3组合物对支气管炎的治疗作用
Bcl-2家族在各类刺激信号引起的凋亡中起到关键的作用,是最重要的凋亡调节蛋白,Bcl-2增高,抑制细胞凋亡。Fas及其配体FasL是细胞凋亡的膜表面分子,Fas基因产物是细胞膜表面受体蛋白,它与T淋巴细胞膜上FasL结合,向细胞内传递细胞凋亡信息,诱导靶细胞发生凋亡。Bcl-2增加和Fas减少的共同作用可使受损伤的肺组织气管、支气管黏膜上皮细胞的病理性凋亡减少,使肺组织恢复正常的生理结构,以减轻气道炎症的发生发展,从而治疗以气道炎症为主要发病机制的咳嗽、哮喘等症。
1急性支气管炎模型建立
取健康昆明种小鼠48只,雌雄各半,体重18-22g,随机选取34只在自制烟熏箱中用烟叶和刨花各50g早晚各熏蒸1次,1次30min,连续熏蒸7d,制备急性气管炎模型。2苏木素-伊红(HE)染色法判定急性支气管炎模型建立
分别随机选取模型组和空白组小鼠各4只,利用20%乌拉坦将其麻醉,取出肺组织包埋。利用恒冷切片机对组织进行连续切片,片厚10μm,将组织切片贴于静电吸附载玻片上,室温自然干燥,将切片密封于切片盒中,-80℃保存。冰冻切片自冰箱取出,室温自然晾干;70%,80%,90%乙醇分别固定5-8s,蒸馏水稍洗5-10s;苏木精染液(50-60℃)染色30s,流水洗去苏木素液5-10s;l%盐酸乙醇分化液分化5-8s,流水洗5-10s;0.5%氨水返蓝液10-15s,流水冲洗10-20s;伊红染液染色5-8s,流水冲洗5-10s;70%,80%,90%乙醇分别脱水5-8s,切片晾干,中性树胶封片。置于倒置显微镜下观察肺组织结构变化。
3免疫荧光组织化学染色检测各组小鼠肺组织Bcl-2和Fas蛋白表达
小鼠急性支气管炎模型建立成功后将模型组小鼠30只随机分为3组(每组10只,雌雄各半):模型组、川贝雪梨糖浆组(11.7mL·kg-1)、组合物组(180mg.kg-1),另取正常饲养小鼠10只为空白组。各造模组从确认造模成功后第1天起开始灌胃给药,每日1次,用药7d;模型组和空白组给予等体积60%蔗糖溶液灌胃。治疗7d后处死小鼠,开胸取出肺组织,制备病理切片,取出肺切片,置于室温平衡30min后,经4%多聚甲醛固定30min,PBS轻轻润洗5min×3次;加入1%Triton X100透化30min,PBS洗5min×3次;3%BSA溶液封闭1h,PBS洗5min×3次;加入一抗(兔抗Bcl2,Fas,1∶150),4℃孵育过夜;次日PBS轻轻洗涤3次后加入Cy3标记的种属特异性二抗(1∶200),避光室温孵育1h,PBS洗5min×3次;加入DAPI染色液避光室温孵育15min,PBS洗涤3次;抗荧光淬灭封片剂封片,于荧光显微镜下观察。每组小鼠选取10张切片标本,观察各个肺组织切片,使用Image-Pro Plus 6.0图像分析软件分析其积分吸光度IA,IA越大蛋白表达量越高。
4统计学方法
采用SPSS 17.0统计软件,数据以珋x±s表示,组间比较采用单因素方差分析,多重比较采用Student-Newman-Keuls test(SNK)检验,P<0.05为有统计学意义。
5结果
5.1成功建立小鼠急性支气管炎模型
模型组可见支气管黏膜充血,肿胀,黏膜下有中性粒细胞浸润,分泌物增加,肺泡上皮增生明显等明显损伤,正常组小鼠可见肺内各级组织明显,结构清晰,无病理损伤。证明小鼠急性支气管炎模型制备成功。
5.2组合物对各组小鼠肺组织Bcl-2和Fas蛋白表达的影响
Bcl-2蛋白和Fas蛋白表达检测结果显示:与正常对照组比较,模型组Bcl-2蛋白表达明显降低,Fas蛋白表达明显增高,说明造模成功;川贝雪梨糖浆组、组合物组与模型组相比Bcl-2蛋白表达明显升高、Fas蛋白表达明显降低,组间比较有统计学差异(P<0.01);组合物组与川贝雪梨糖浆组比较Bcl-2升高、Fas降低更加显著,组间比较有统计学意义(P<0.05)。
以上结果充分表明:本发明提供的中药组合物可显著提高急性支气管炎小鼠Bcl-2蛋白表达,降低Fas蛋白表达,并且效果显著好于川贝止咳糖浆的效果。具体结果见表4。
表4组合物对各组小鼠肺组织Bcl-2和Fas蛋白表达的影响
与模型组相比,##p<0.01;
与川贝雪梨糖浆组相比,﹩p<0.05。
Claims (10)
1.一种含何首乌、芦荟、决明子、枸杞子、阿胶、人参、白术、枳实的中药组合物在制备呼吸系统炎症防治药物中的用途。
2.如权利要求1所述的用途,其特征在于,所述的中药组合物中各成分以重量份计为:何首乌60-150重量份、芦荟100-200重量份、决明子80-180重量份、枸杞子30-150重量份、阿胶30-150重量份、人参20-100重量份、白术20-100重量份、枳实50-200重量份;优选为:何首乌120重量份、芦荟160重量份、决明子140重量份、枸杞子75重量份、阿胶75重量份、人参50重量份、白术50重量份、枳实120重量份。
3.如权利要求1-2所述的用途,其特征在于,所述的中药组合物还可以含有药学上可接受的辅料。
4.如权利要求3所述的用途,其特征在于,所述的中药组合物制备成药物制剂。
5.如权利要求4所述的用途,其特征在于,所述的所述的药物制剂为片剂,胶囊剂,颗粒剂中的任意一种。
6.如权利要求1所述的用途,其特征在于,所述的呼吸系统炎症为肺炎或支气管炎。
7.如权利要求6所述的用途,其特征在于,所述的肺炎由克莱伯杆菌,金黄色葡萄球菌或肺炎链球菌中的一种或多种致病菌引起。
8.如权利要求1所述的用途,其特征在于,所述的中药组合物可使肺炎患者肺组织恢复正常的生理结构、降低肺炎模型大鼠的白细胞和中性粒细胞水平、降低肺炎患者TNF-α,IL-1β,IL-6水平。
9.如权利要求1所述的用途,其特征在于,所述的中药组合物可显著提高急性支气管炎小鼠Bcl-2水平、降低Fas水平。
10.如权利要求1所述的用途,其特征在于,所述的中药组合物在用于咳嗽的治疗时的用药剂量为3mg/kg.d-300mg/kg.d,优选为30mg/kg.d。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911058534.9A CN112755108A (zh) | 2019-11-01 | 2019-11-01 | 一种中药组合物在制备呼吸系统炎症防治药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911058534.9A CN112755108A (zh) | 2019-11-01 | 2019-11-01 | 一种中药组合物在制备呼吸系统炎症防治药物中的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112755108A true CN112755108A (zh) | 2021-05-07 |
Family
ID=75691970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911058534.9A Pending CN112755108A (zh) | 2019-11-01 | 2019-11-01 | 一种中药组合物在制备呼吸系统炎症防治药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112755108A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109464570A (zh) * | 2018-11-23 | 2019-03-15 | 鲁南制药集团股份有限公司 | 一种首荟通便胶囊制备工艺 |
-
2019
- 2019-11-01 CN CN201911058534.9A patent/CN112755108A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109464570A (zh) * | 2018-11-23 | 2019-03-15 | 鲁南制药集团股份有限公司 | 一种首荟通便胶囊制备工艺 |
Non-Patent Citations (3)
Title |
---|
李凤玲: "羊耳菊水提物对肺炎克雷伯菌所致重症肺炎大鼠的抗炎效果及机制", 《世界中医药》, vol. 12, no. 10, pages 2438 - 2442 * |
李秀丽等: "羚贝止咳糖浆止咳、平喘作用及其作用机制", 《中国实验方剂学杂志》, vol. 23, no. 22, pages 149 - 154 * |
陆小左等主编, 河北科学技术出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022057360A1 (zh) | 一种用于冬季防治呼吸道疾病的药物组合物 | |
CN103285179A (zh) | 一种治疗急性咽炎的中药制剂及其制备方法 | |
CN112294911A (zh) | 一种治疗肺热咳嗽的中药组合物 | |
CN111329950A (zh) | 中药组合物及其制剂在制备治疗急性肺损伤的药物中的用途 | |
CN112755108A (zh) | 一种中药组合物在制备呼吸系统炎症防治药物中的用途 | |
US10772933B2 (en) | Medicament for treating pulmonary tuberculosis | |
CN111407846B (zh) | 一种治疗慢性阻塞性肺病的中药方剂及其制备方法 | |
CN111084862B (zh) | 用于防治家禽肺热咳喘症的中药口服液及其制备方法 | |
CN102397458B (zh) | 一种治疗老年人肺炎的药物组合物及其制备方法 | |
CN114796183B (zh) | 益母草碱在制备用于预防或治疗呼吸系统疾病的药物中的应用 | |
CN112472749A (zh) | 用于治疗稳定期慢阻肺的中药颗粒剂及其制备方法和用途 | |
CN113577158A (zh) | 一种治疗急性肺损伤的衢枳壳有效成分组及其制备方法与应用 | |
CN112826887B (zh) | 一种中药组合物在制备咳嗽防治药物中的用途 | |
CN110575505A (zh) | 治疗急性支气管炎、慢性支气管炎急性发作的药物及其制备方法与应用 | |
CN106913627B (zh) | 一种小儿蒲地蓝消炎糖浆及其制备方法 | |
CN115845021B (zh) | 一种用于预防和治疗肺纤维化的中药组合物及其制备方法 | |
CN106581520B (zh) | 一种治疗弥漫性肺间质纤维化肺气虚证的中药颗粒 | |
CN1939413B (zh) | 一种复方北豆根药物组合物 | |
CN113827636B (zh) | 藏四味清肺合剂及其在制备治疗呼吸系统疾病药物中的应用 | |
CN101940704A (zh) | 一种治疗哮喘的复方组合药物及其制备方法 | |
CN116211993B (zh) | 老慢清组合物及其制备方法 | |
US20100048457A1 (en) | Glycoprotein for treating chronic obstructive pulmonary diseases | |
CN102233026B (zh) | 一种药物组合物及其制备方法和用途 | |
CN115813988B (zh) | 一种中药制剂组合物及其制备方法、应用 | |
CN108355124A (zh) | 一种治疗气道粘液高分泌的中药组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210507 |